当前位置: X-MOL 学术RSC Med. Chem. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
A promising anticancer drug: a photosensitizer based on the porphyrin skeleton
RSC Medicinal Chemistry ( IF 4.1 ) Pub Date : 2020-02-25 , DOI: 10.1039/c9md00558g
Qizhi Zhang 1, 2 , Jun He 3 , Wenmei Yu 1, 2 , Yanchun Li 1, 2 , Zhenhua Liu 1, 2 , Binning Zhou 1, 2 , Yunmei Liu 1, 2
Affiliation  

Photodynamic therapy (PDT) is a minimally invasive combination of treatments that treat tumors and other diseases by using photosensitizers, light and oxygen to produce cytotoxic reactive oxygen species (ROS) inducing tumor cell apoptosis. Photosensitizers are the key part of PDT for clinical application and experimental research, and most of them are porphyrin compounds at present. Due to their unique affinity for tumor tissues, porphyrins are not only excellent photosensitizers, but also good carriers to transport other active drugs into tumor tissues, which can exert synergistic anticancer effects of PDT and chemotherapy. This article reviews the clinical development of porphyrin photosensitizers and the research status of porphyrin containing bioactive groups. Finally, future perspectives and the current challenges of photosensitizers based on the porphyrin skeleton are discussed.

中文翻译:

一种有前途的抗癌药物:基于卟啉骨架的光敏剂

光动力疗法(PDT)是一种微创治疗组合,通过使用光敏剂、光和氧气产生细胞毒性活性氧(ROS)诱导肿瘤细胞凋亡来治疗肿瘤和其他疾病。光敏剂是PDT临床应用和实验研究的关键部分,目前以卟啉类化合物居多。由于其对肿瘤组织独特的亲和力,卟啉不仅是优良的光敏剂,也是将其他活性药物转运至肿瘤组织的良好载体,可以发挥PDT和化疗的协同抗癌作用。本文综述了卟啉光敏剂的临床发展以及含卟啉生物活性基团的研究现状。最后,讨论了基于卟啉骨架的光敏剂的未来前景和当前挑战。
更新日期:2020-02-25
down
wechat
bug